

ForPatients

by Roche

Advanced Prostate Cancer Metastatic Prostate Cancer

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

Trial Status

Not Yet Recruiting

Trial Runs In

0 Countries

Trial Identifier

NCT07567846 GO46445

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.

Genentech, Inc.

Sponsor

Phase 1/Phase 2

Phase

NCT07567846 GO46445

Trial Identifiers

Eligibility Criteria:

Gender

Male

Age

>=18 Years

Healthy Volunteers

No
